A5001895894- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- PI3K/AKT/mTOR signaling in cancer
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Inflammatory Biomarkers in Disease Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Brain Metastases and Treatment
- RNA modifications and cancer
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- Metastasis and carcinoma case studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Myasthenia Gravis and Thymoma
National Hospital Organization Kyushu Cancer Center
2016-2025
Taiho Pharmaceutical (Japan)
2016
Chugai Pharma (United States)
2016
Kyowa Hakko Kirin (Singapore)
2016
Novartis (Germany)
2016
Daiichi Sankyo (United Kingdom)
2016
AstraZeneca (Brazil)
2016
Novartis (France)
2016
Astellas Pharma (United Kingdom)
2016
Sumitomo Dainippon Pharma (Japan)
2016
Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and amplifications 1 6%. Capmatinib, a selective inhibitor of the receptor, has shown activity models various types activation.
IntroductionTo evaluate the efficacy and safety of osimertinib plus bevacizumab for previously untreated patients with advanced nonsquamous NSCLC harboring EGFR-sensitizing mutations.MethodsWe conducted a randomized, open-label, phase 2 study at 21 institutions in Japan. Previously mutations received either (80 mg, daily) (15 mg/kg, every 3 wk) or monotherapy, were stratified according to sex, stage, EGFR mutation status. The primary end point was progression-free survival (PFS)...
Background PD-L1 expression on tumor cells is a marker of PD-1/PD-L1 antibody treatment efficacy for advanced non-small cell lung cancer (NSCLC). (atezolizumab) prolongs overall survival (OS) compared with platinum doublet as first-line NSCLC high expression. Bevacizumab enhanced cytotoxic agent and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in non-squamous (NS)-NSCLC, antibodies preclinical models. Methods This single-arm phase II study investigated clinical benefits...
Immunotherapy targeting programmed cell death-1 (PD-1) and death-ligand 1 (PD-L1) has become the forefront strategy for systemic therapy in advanced non-small lung cancer (NSCLC) patients. PD-L1 expression on tumor cells been reported as an eligible biomarker of response to such immunotherapies. However, useful biomarkers atezolizumab, anti antibody, are unestablished.We retrospectively analyzed clinicopathological characteristics including NSCLC patients treated with atezolizumab from...
IntroductionThis phase 2 trial evaluated the efficacy and safety of brigatinib in patients with advanced ALK-positive NSCLC refractory to alectinib or other ALK tyrosine kinase inhibitors (TKIs).MethodsThis single-arm, multicenter, open-label study Japanese consisted a lead-in followed by an expansion stage TKI those naive for TKI. Patients received 180 mg once daily 7-day at 90 daily. Primary end point was independent review committee (IRC)–assessed confirmed objective response rate per...
Background Studies have suggested that chemotherapy after immune checkpoint inhibitors may confer an improved response for non–small cell lung cancer (NSCLC). However, potential selection bias in such studies has not been addressed. We therefore applied propensity score analysis to investigate the efficacy of PD-1 inhibitor treatment (CAP) compared with alone. Methods conducted a retrospective observational cohort study patients treated at 47 institutions across Japan between April 1, 2014...
Background: Combined chemotherapy with nivolumab and ipilimumab (NIC) improves survival outcomes in treatment-naïve patients advanced non-small cell lung cancer (NSCLC). However, these have a higher incidence of treatment-related deaths (TRDs) especially due to NIC. The aim this study is devise risk stratification score for selecting lower or TRD-risk. Methods: A dataset from the JCOG2007 used, which compared NIC combined pembrolizumab (PC). TRD was built an adaptive LASSO regression...
Abstract Purpose: This study was performed to confirm the superiority in overall survival (OS) of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) (gefitinib or osimertinib) monotherapy versus EGFR-TKI with intercalation cisplatin plus pemetrexed as first-line treatment for patients advanced non-squamous non-small cell lung cancer (NSqNSCLC) harboring EGFR mutation. Patients and Methods: an open-label, multicenter, randomized phase III study. chemotherapy-naïve recurrent...
// Yutaka Fujiwara 1 , Masayuki Takeda 2 Noboru Yamamoto Kazuhiko Nakagawa Kaname Nosaki 3 Ryo Toyozawa Chihiro Abe 4 Ryota Shiga Kenji Nakamaru and Takashi Seto Department of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan Medical Oncology, Kindai University Faculty Medicine, Osaka-Sayama-shi, Osaka 589-8511, Thoracic Hospital Organization Kyushu Center, Minami-ku, Fukuoka-shi, Fukuoka 811-1395, Daiichi Sankyo Co., Ltd., Hiromachi, Shinagawa-ku,...
Pembrolizumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody, has been shown to yield a durable response and significant survival benefit in some non-small lung cancer (NSCLC) patients. Recent studies have that the Controlling Nutritional Status (CONUT) score, novel nutritional index, can be useful for predicting prognosis malignancies. However, its usefulness clinical outcome of immune-checkpoint inhibitor (ICI) treatment patients with NSCLC not clarified. The aim this study...
The impact of epidermal growth factor receptor (EGFR) status and the use EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy have not been well discussed only in recurrent non-small-cell lung cancer (NSCLC). purpose this study was to identify prognostic factors associated with post-recurrence survival after surgical resection NSCLC terms EGFR mutation EGFR-TKI therapy.From 2000 through 2011, 1237 consecutive patients underwent pulmonary at our institution. Of these patients, 280 experienced...
Immunotherapy is the fourth leading therapy for lung cancer following surgery, chemotherapy and radiotherapy. Recently, several studies have reported about potential association between gut microbiome therapeutic response to immunotherapy. Nevertheless, specific composition of or combination microbes that truly predict efficacy immunotherapy not definitive. The present multicentre, prospective, observational study aims discover predicting in using artificial intelligence. main inclusion...
The phase 2, single-arm, multicenter, open-label J-ALTA study evaluated the efficacy and safety of brigatinib in Japanese patients with advanced ALK+ non-small-cell lung cancer (NSCLC). One expansion cohort enrolled previously treated ALK tyrosine kinase inhibitors (TKIs); main included prior alectinib ± crizotinib. second TKI-naive NSCLC. All received 180 mg once daily (7-day lead-in at 90 daily). Among 47 cohort, 5 (11%) remained on end (median follow-up: 23 months). In this independent...
Background The aim of this study was to evaluate the potential liquid biopsy for prediction efficacy epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) treatment and assessment changes in genetic alterations during such treatment. Methods Plasma samples were prospectively collected from non–small cell lung cancer patients with EGFR ‐activating mutations EGFR‐TKI until disease progression analyzed droplet digital polymerase chain reaction other somatic next‐generation...